Hypoglycaemic Molecules for the Management of Diabetes Mellitus from Marine Sources.

Diabetes mellitus (DM) is a chronic metabolic disorder recognized as a major health problem globally. A defective insulin activity contributes to the prevalence and expansion of DM. Treatment of DM is often hampered by limited options of conventional therapies and adverse effects associated with existing procedures.

A review of MMP-2 structures and binding mode analysis of its inhibitors to strategize structure-based drug design.

The protease enzyme, matrix metalloproteinase-2 (MMP-2) has been a target of choice for the drug development due to its multi-façade involvement in numerous diseased conditions including cancer. To find a selective MMP-2 inhibitor several computational strategies are employed in its design and discovery. In these strategies, protein structure of MMP-2 is an inevitable part to formulate effective structure-based drug design (SBDD) of selective MMP-2 inhibitors.

Ligand-based design of anticancer MMP2 inhibitors: a review.

MMP2, a Zn-dependent metalloproteinase, is related to cancer and angiogenesis. Inhibition of this enzyme might result in a potential antimetastatic drug to leverage the anticancer drug armory. or computer-aided ligand-based drug design is a method of rational drug design that takes multiple chemometrics (i.

Urea transporter and its specific and nonspecific inhibitors: State of the art and pharmacological perspective.

Hypertension is a major concern for a wide array of patients. The traditional drugs are commonly referred as 'water pills' and these molecules have been successful in alleviating hypertension. However, this comes at the high expense of precious electrolytes in our body.